UBS (Lux) Equity SICAV - China Health Care (USD) U-X-acc

Reference Data

ISIN LU2389359030
Valor Number 113841311
Bloomberg Global ID UBHCUUX LX
Fund Name UBS (Lux) Equity SICAV - China Health Care (USD) U-X-acc
Fund Provider UBS Asset Management Switzerland AG, Zurich Basel, Switzerland
Phone: +41 61 288 75 01
E-Mail: sh-ubs-funds-feedback@ubs.com
Web: www.ubs.com/fonds
Fund Provider UBS Asset Management Switzerland AG, Zurich
Representative in Switzerland UBS Fund Management (Switzerland) AG
Basel
Phone: +41 61 288 49 10
Distributor(s) UBS Global Asset Management
Basel
Phone: +41 61 288 20 20
Asset Class Equities
EFC Category Equity Health Care
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The actively managed sub-fund invests mainly in shares and other equity interests of companies related to the healthcare sector domiciled in the People’s Republic of China (“PRC”) or other companies that have close economic links with the PRC. These investments contain securities listed within the PRC (onshore) or outside of the PRC (offshore). This sub-fund promotes environmental and/or social characteristics and complies with Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector (“SFDR”).
Peculiarities

Fund Prices

Current Price * 8,874.13 USD 30.09.2024
Previous Price * 8,388.50 USD 27.09.2024
52 Week High * 9,474.85 USD 06.11.2023
52 Week Low * 7,086.42 USD 30.07.2024
NAV * 8,874.13 USD 30.09.2024
Issue Price * 8,874.13 USD 30.09.2024
Redemption Price * 8,874.13 USD 30.09.2024
Closing Price *
Indicative Minimum Price
Fund Assets *** 2,847,030
Unit/Share Assets *** 1,614,984
Trading Information SIX

Performance

YTD Performance -0.58% 29.12.2023
30.09.2024
YTD Performance (in CHF) -0.64% 29.12.2023
30.09.2024
1 month +18.14% 30.08.2024
30.09.2024
3 months +21.20% 02.07.2024
30.09.2024
6 months +15.21% 02.04.2024
30.09.2024
1 year +0.75% 09.10.2023
30.09.2024
2 years +7.97% 30.09.2022
30.09.2024
3 years -9.52% 22.08.2022
30.09.2024
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Innovent Biologics Inc 9.18%
Jiangsu Hengrui Pharmaceuticals Co Ltd Class A 7.19%
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A 6.84%
Tencent Holdings Ltd 5.51%
Yunnan Baiyao Group Co Ltd Class A 4.85%
BeiGene Ltd Ordinary Shares 3.95%
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Class H Shares 3.18%
Akeso Inc Ordinary Shares 2.65%
Legend Biotech Corp ADR 2.46%
BeiGene Ltd Class A 2.37%
Last data update 31.08.2024

Cost / Risk

TER 0.02%
TER date 31.05.2023
Performance Fee *** 0.00%
PTR
Max. Management Fee *** 0.00%
Ongoing Charges *** 0.03%
SRRI ***
SRRI date *** 31.08.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)